A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis
Primary Purpose
Bacterial Enteritis
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
OPS-2071 tablet
Sponsored by
About this trial
This is an interventional treatment trial for Bacterial Enteritis
Eligibility Criteria
Inclusion Criteria:
- The patient provides written, informed consent before the clinical trial is initiated
- The patient has distinctive symptoms and findings of bacterial enteritis
- The patient has bacterial enteritis with one or more of the following causative pathogens either proven or presumed: C. difficile, Salmonella, Campylobacter, pathogenic E. coli, and other bacteria estimated to cause bacterial enteritis
- The patient and his/her partner are willing to take contraceptive measures from initiation of investigational medicinal products (IMPs) to 4 weeks after administration of IMPs
Exclusion Criteria:
- The patient has severe or progressive underlying disease or complication, making it difficult to ensure safety in the study or proper efficacy assessment
- The patient has a current diagnosis or history of convulsive disorders, such as convulsion and epilepsy
- The patient has a severe hepatic dysfunction
- The patient has a severe cardiac dysfunction
- The patient has cardiac arrhythmia or congenital or sporadic long QTc syndrome. Or the patient is treated with a drug reported to prolong QTc interval
- The patient has a moderate or severe renal dysfunction
- Women with confirmed or suspected pregnancy or breast-feeding women
- Patients judged to be ineligible by the investigator for any other reasons
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Experimental
Arm Label
OPS-2071 50mg/day
OPS-2071 100 mg/day
OPS-2071 200 mg/day
OPS-2071 400 mg/day
Arm Description
OPS-2071 50 mg/day:25 mg tablet administered orally twice daily
OPS-2071 100 mg/day:50 mg tablet administered orally twice daily
OPS-2071 200 mg/day:100 mg tablet administered orally twice daily
OPS-2071 400 mg/day:100 mg two tablets administered orally twice daily
Outcomes
Primary Outcome Measures
Bacterial Elimination Rate (BER) in the CDI and EI Groups
Judged according to the assessment criteria for the bacterial strain isolated as the causative pathogen based on the data from the microbiological examination. Analysis was performed by disease group and by dose, and by minimum inhibitory concentration (MIC) values of OPS-2071 for each of the causative strains (Enterotoxigenic E. coli, Enteroaggregative E. coli, Campylobacter sp., C. jejuni, S. aureus, K. oxytoca, and C. perfringens for the EI group). Data were shown as all strains total.
Concerning microbiological outcome by causative strain, bacteria elimination rate (BER) and its 95% confidence interval (CI) were calculated. The BER was the proportion of causative strains assessed as either "Excellent" or "Good" except for those assessed as "unknown/indeterminate".
Maximum Plasma Concentration (Cmax) of OPS-2071 on Day 4
We measured OPS-2071 concentration in plasma and evaluated Cmax of OPS-2071 in plasma.
Time to Maximum Plasma Concentration (Tmax) of OPS-2071 on Day 4
We measured OPS-2071 concentration in plasma and evaluated tmax of OPS-2071 in plasma.
Secondary Outcome Measures
The Recurrence Rate of CDI After Multiple Doses of OPS-2071 (for CDI Group Only)
CDI recurrence rate at follow-up (Day 38) or withdrawal was calculated. CDI recurrence rate was the proportion of the subjects judged as "recurrent" against evaluable subjects, except for those with missing data.
The Time to Resolution of Diarrhea After Multiple Doses of OPS-2071
The time from the start of dosing until the first formed stool (except in cases where liquid or unformed stools recurred) was evaluated as time to resolution of diarrhea. If formed stool has not been observed, then the subject will be handled as missing data.
Stool Frequency Per Day After Multiple Doses of OPS-2071
Under each disease group, the improvement of clinical symptoms (stool frequency/day) were assessed.
Number of Subjects With Formed Stool, Liquid or Unformed Stool, and Bloody Stool After Multiple Doses of OPS-2071
Under each disease group, the improvement of clinical symptoms ((i.e. formed stool, liquid or unformed stool [3 and more times], and presence of bloody stool) were assessed.
Number of Subjects With Abdominal Pain, Nausea, and Vomiting After Multiple Doses of OPS-2071
Under each disease group, he improvement of clinical symptoms (i.e. presence of abdominal pain, nausea, and vomiting) were assessed.
Clinical Response Rate (CRR) in the CDI and EI Groups
The CRR and 95% CI at each evaluation time point were calculated. The CRR was calculated as the proportion of the subjects judged as "clinical cure" or "clinical improvement" against evaluable subjects, except for those with missing data.
Full Information
NCT ID
NCT02473393
First Posted
June 8, 2015
Last Updated
March 1, 2021
Sponsor
Otsuka Pharmaceutical Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT02473393
Brief Title
A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
August 20, 2015 (Actual)
Primary Completion Date
March 14, 2017 (Actual)
Study Completion Date
March 14, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Otsuka Pharmaceutical Co., Ltd.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To assess safety, efficacy and pharmacokinetics of multiple dosesin patients with Bacterial Enteritis caused by Clostridium difficile infection(CDI) or Enteric infection.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bacterial Enteritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Arm Title
OPS-2071 50mg/day
Arm Type
Experimental
Arm Description
OPS-2071 50 mg/day:25 mg tablet administered orally twice daily
Arm Title
OPS-2071 100 mg/day
Arm Type
Experimental
Arm Description
OPS-2071 100 mg/day:50 mg tablet administered orally twice daily
Arm Title
OPS-2071 200 mg/day
Arm Type
Experimental
Arm Description
OPS-2071 200 mg/day:100 mg tablet administered orally twice daily
Arm Title
OPS-2071 400 mg/day
Arm Type
Experimental
Arm Description
OPS-2071 400 mg/day:100 mg two tablets administered orally twice daily
Intervention Type
Drug
Intervention Name(s)
OPS-2071 tablet
Primary Outcome Measure Information:
Title
Bacterial Elimination Rate (BER) in the CDI and EI Groups
Description
Judged according to the assessment criteria for the bacterial strain isolated as the causative pathogen based on the data from the microbiological examination. Analysis was performed by disease group and by dose, and by minimum inhibitory concentration (MIC) values of OPS-2071 for each of the causative strains (Enterotoxigenic E. coli, Enteroaggregative E. coli, Campylobacter sp., C. jejuni, S. aureus, K. oxytoca, and C. perfringens for the EI group). Data were shown as all strains total.
Concerning microbiological outcome by causative strain, bacteria elimination rate (BER) and its 95% confidence interval (CI) were calculated. The BER was the proportion of causative strains assessed as either "Excellent" or "Good" except for those assessed as "unknown/indeterminate".
Time Frame
CDI group: screening, Day 4 and Day 11 (end of treatment), EI group: screening, Day 4 and Day 8 (end of treatment)
Title
Maximum Plasma Concentration (Cmax) of OPS-2071 on Day 4
Description
We measured OPS-2071 concentration in plasma and evaluated Cmax of OPS-2071 in plasma.
Time Frame
Inpatient: 1h, 2h, and 4h after morning administration
Title
Time to Maximum Plasma Concentration (Tmax) of OPS-2071 on Day 4
Description
We measured OPS-2071 concentration in plasma and evaluated tmax of OPS-2071 in plasma.
Time Frame
1h, 2h, and 4h after morning administration
Secondary Outcome Measure Information:
Title
The Recurrence Rate of CDI After Multiple Doses of OPS-2071 (for CDI Group Only)
Description
CDI recurrence rate at follow-up (Day 38) or withdrawal was calculated. CDI recurrence rate was the proportion of the subjects judged as "recurrent" against evaluable subjects, except for those with missing data.
Time Frame
Day 38
Title
The Time to Resolution of Diarrhea After Multiple Doses of OPS-2071
Description
The time from the start of dosing until the first formed stool (except in cases where liquid or unformed stools recurred) was evaluated as time to resolution of diarrhea. If formed stool has not been observed, then the subject will be handled as missing data.
Time Frame
CDI group: Day 4, Day 11 (end of treatment) and Day 38, EI group: Day 4 and Day 8 (end of treatment)
Title
Stool Frequency Per Day After Multiple Doses of OPS-2071
Description
Under each disease group, the improvement of clinical symptoms (stool frequency/day) were assessed.
Time Frame
CDI group: screening, Day 4, Day 11 (end of treatment) and Day 38, EI group: screening, Day 4 and Day 8 (end of treatment)
Title
Number of Subjects With Formed Stool, Liquid or Unformed Stool, and Bloody Stool After Multiple Doses of OPS-2071
Description
Under each disease group, the improvement of clinical symptoms ((i.e. formed stool, liquid or unformed stool [3 and more times], and presence of bloody stool) were assessed.
Time Frame
CDI group: screening, Day 4, Day 11 (end of treatment) and Day 38, EI group: screening, Day 4 and Day 8 (end of treatment)
Title
Number of Subjects With Abdominal Pain, Nausea, and Vomiting After Multiple Doses of OPS-2071
Description
Under each disease group, he improvement of clinical symptoms (i.e. presence of abdominal pain, nausea, and vomiting) were assessed.
Time Frame
CDI group: screening, Day 4, Day 11 (end of treatment) and Day 38, EI group: screening, Day 4 and Day 8 (end of treatment)
Title
Clinical Response Rate (CRR) in the CDI and EI Groups
Description
The CRR and 95% CI at each evaluation time point were calculated. The CRR was calculated as the proportion of the subjects judged as "clinical cure" or "clinical improvement" against evaluable subjects, except for those with missing data.
Time Frame
CDI group: Day 4 and Day 11 (end of treatment), EI group: Day 4 and Day 8 (end of treatment)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patient provides written, informed consent before the clinical trial is initiated
The patient has distinctive symptoms and findings of bacterial enteritis
The patient has bacterial enteritis with one or more of the following causative pathogens either proven or presumed: C. difficile, Salmonella, Campylobacter, pathogenic E. coli, and other bacteria estimated to cause bacterial enteritis
The patient and his/her partner are willing to take contraceptive measures from initiation of investigational medicinal products (IMPs) to 4 weeks after administration of IMPs
Exclusion Criteria:
The patient has severe or progressive underlying disease or complication, making it difficult to ensure safety in the study or proper efficacy assessment
The patient has a current diagnosis or history of convulsive disorders, such as convulsion and epilepsy
The patient has a severe hepatic dysfunction
The patient has a severe cardiac dysfunction
The patient has cardiac arrhythmia or congenital or sporadic long QTc syndrome. Or the patient is treated with a drug reported to prolong QTc interval
The patient has a moderate or severe renal dysfunction
Women with confirmed or suspected pregnancy or breast-feeding women
Patients judged to be ineligible by the investigator for any other reasons
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yoshitaka Kotobuki
Organizational Affiliation
Otsuka Pharmaceutical Co., Ltd.
Official's Role
Study Director
Facility Information:
City
Kanto, Region
Country
Japan
City
Seoul
Country
Korea, Republic of
City
Singapore
Country
Singapore
12. IPD Sharing Statement
Learn more about this trial
A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis
We'll reach out to this number within 24 hrs